Ethyl2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carb

In the convergent synthesis of Febuxostat, ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate is the penultimate intermediate prior to conversion of the 3‑formyl group to a nitrile. The downstream transformation, typically executed as a one‑pot oximation‑dehydration sequence, is initiated by dissolving the solid intermediate in anhydrous N,N‑dimethylformamide (DMF, water content ≤ 300 ppm by Karl Fischer titration per ASTM E1064‑22) at 20–25 °C under a nitrogen blanket. Hydroxylamine hydrochloride (1.05–1.10 molar equivalents relative to the aldehyde) is added as a single portion, followed by pyridine (1.20 equiv.) acting as an acid scavenger; the resulting slurry ages for 60–90 min until the intermediate dissolves and in‑process HPLC (C18 column, acetonitrile/0.1% phosphoric acid gradient, UV 230 nm) indicates aldehyde consumption ≤ 2.0 area%. The oximation mass is then cooled to 0–5 °C, and phosphorus oxychloride (POCl₃, 1.30–1.40 equiv.) is metered in over 45–60 min to maintain an internal temperature below 10 °C—exceeding this threshold triggers exothermic decomposition of the phosphorylated oxime adduct and reduces nitrile yield by 8–12 absolute percent. After a 3‑hour hold at 5–10 °C, the reaction is quenched into ice‑cold water, and the precipitated crude Febuxostat nitrile ester is isolated by centrifugation (RCF 800–1000 × g) and washed with deionized water until the filtrate conductivity drops below 50 µS cm⁻¹. The wet cake is dissolved in ethyl acetate, treated with activated carbon, and crystallized through gradual n‑heptane addition to furnish the cyano ester; subsequent alkaline hydrolysis and acidification yield Febuxostat API that complies with ICH Q11 criteria for starting material justification. Throughout this cascade, the aldehyde intermediate charging ratio is calibrated to deliver a theoretical batch size of 25.0–30.0 kg of Febuxostat per 100‑L glass‑lined reactor volume; deviations in formyl‑group stoichiometry—reflected by residual aldehyde > 0.15% by GC after oximation—are traced to incomplete dehydration of the oxime‑phosphate intermediate. Occupational exposure limits for the aldehyde are aligned with a band of 10–50 µg m⁻³ as an 8‑hour TWA, derived from a health‑based risk assessment conducted per ASTM E2672‑22. GMP oversight follows ICH Q7 (Section 9.2 cleaning validation, Section 5.3 in‑process controls), with release specifications including assay ≥ 98.5%, related substance “aldehyde” ≤ 0.10% by HPLC, and residual phosphorus ≤ 5 ppm. The terminal finished good is Febuxostat USP, a xanthine oxidase inhibitor indicated for hyperuricaemia.

What Limits the Yield of the Isolated Oxime Intermediate in Multi‑Step Febuxostat Routes?

When a decision is taken to isolate the oxime—ethyl 2-(3‑(hydroxyiminomethyl)‑4‑isobutoxyphenyl)‑4‑methylthiazole‑5‑carboxylate—rather than telescoping it directly into dehydration, the thermal lability of the aldoxime moiety under alkaline conditions becomes the dominant processing constraint. In the event, the aldehyde intermediate (1.0 kg, 2.86 mol) is dissolved in methanol (4.0 L kg⁻¹) at 15–20 °C, and a pre‑cooled solution of hydroxylamine hydrochloride (210 g, 3.00 mol, i.e., 1.05 equiv.) and sodium acetate trihydrate (490 g, 3.60 mol) in water (1.2 L) is added while maintaining the reaction mass below 25 °C. The pH of the mixture stabilises at 6.0–6.5, a range deliberately chosen to suppress both free‑hydroxylamine‑promoted amide‑side‑product generation and the Cannizzaro disproportionation that becomes kinetically competitive above pH 8.5. After 2 h of gentle agitation with an anchor impeller at 40 rpm in a glass‑lined Pfaudler reactor, the precipitated oxime is collected on an agitated Nutsche filter, washed with chilled methanol‑water (1:1 v v⁻¹, 2 × 1.0 L) and dried under vacuum at 35–40 °C (jacket temperature never exceeding 45 °C to avoid syn‑anti isomerisation that lowers the melting point and creates sticky solids). The dried oxime typically exhibits a purity of 99.2–99.6 area% by HPLC and residual methanol below 100 ppm (ICH Q3C concentration limits for Class 2 solvents applied at the intermediate stage). A key operational peril is the autoxidation of the oxime back to the aldehyde that occurs when the wet cake is exposed to air for more than 8 h; therefore, vacuum drying is commenced within 2 h of filtration. On a 50‑kg pilot‑plant batch, instantaneous jacket‑temperature excursions above 50 °C during drying were found to reduce the isolated yield from the typical 92–94% to 84–87%, with concurrent formation of 0.3–0.5% of the nitrile as a premature dehydration by‑product, quantifiable by LC‑MS in selected ion monitoring mode. The oxime intermediate is subsequently converted to Febuxostat nitrile ester using POCl₃ or a Vilsmeier reagent in a second reaction vessel; yield of the isolated oxime, rather than the aldehyde, now defines the overall material balance. Compliance documentation for the isolated oxime follows the same ICH Q7 supply‑chain oversight as for the aldehyde, with a specification that includes loss on drying ≤ 0.5% (USP <731>) and a limit of 0.15% for the aldehyde starting material. Terminal product remains Febuxostat API.

For chromatographic system suitability testing under the USP-NF monograph for Febuxostat, a reference stock solution of the aldehyde impurity is prepared by dissolving 10.0 mg of ethyl 2-(3-formyl-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate (dried under vacuum over P₂O₅ for 4 h) in 100.0 mL of diluent (acetonitrile : water = 60 : 40 v v⁻¹) to yield a concentration of 0.10 mg mL⁻¹. A 1.0‑mL aliquot is further diluted to 100 mL to obtain the sensitivity solution (1.0 µg mL⁻¹), used to confirm a signal‑to‑noise ratio ≥ 10 for the aldehyde peak at a retention time of approximately 14.7 min on a 5 µm C18 column (250 × 4.6 mm) with detection at 230 nm. This standard is employed to quantify the aldehyde carry‑over in Febuxostat drug substance batches, where the acceptance criterion of ≤ 0.10% is derived from ICH Q3A(R2) identification threshold considerations and from toxicological assessment of the aldehyde as a non‑mutagenic process impurity with a permitted daily exposure (PDE) of 125 µg day⁻¹. In routine QC operations, the standard solution is stored in amber volumetric flasks at 2–8 °C; stability studies have documented a 0.5–0.8% decline in assay after 14 days due to slow air oxidation, so fresh preparation is mandated every 72 h. The aldehyde impurity standard also serves as the retention‑time marker for the Related Substances test prescribed in the manufacturer’s DMF; during method transfer to a contract QC laboratory, an extended ruggedness validation performed per USP <1225> demonstrated that column temperature shifts of ± 3 °C alter the resolution between the aldehyde and the Febuxostat oxime impurity by 0.25–0.30 units, enforcing tighter oven temperature control (23 ± 1 °C). The terminal products whose release relies on this reference material are Febuxostat tablets (40 mg and 80 mg strengths) and the corresponding API; both must conform to ICH Q3B limits for unspecified degradation products. Equipment qualification for the HPLC system follows ISO/IEC 17025:2017 (clause 6.4) with a quarterly performance qualification sequence.

When the Aldehyde Intermediate Serves as a Central Handle for Late‑Stage Diversification in Xanthine Oxidase Inhibitor Programmes

Beyond its role as a linear precursor to Febuxostat, the aldehyde moiety embedded in the 2‑aryl‑4‑methylthiazole‑5‑carboxylate scaffold provides a versatile electrophilic anchor for parallel medicinal chemistry campaigns aimed at modulating clearance or solubility while preserving xanthine‑oxidase‑inhibitory potency. In a typical 96‑well plate format, an automated liquid handler dispenses 0.20 mmol of the aldehyde intermediate (dissolved in anhydrous DMAc, 0.5 mL) per well, followed by addition of 1.10 equiv. of a primary amine in the presence of glacial acetic acid (10 mol %) and sodium triacetoxyborohydride (STAB, 1.50 equiv.) to effect reductive amination. After 16 h of orbital shaking at 25 °C, the crude library members—2‑[3‑(aminomethyl)‑4‑isobutoxyphenyl]‑4‑methylthiazole‑5‑carboxylate derivatives—are purified by mass‑directed preparative HPLC, with typical isolated yields ranging from 45 % to 72 % depending on amine nucleophilicity. These analogues are then hydrolysed to the carboxylic acids and tested in a fluorescence‑based xanthine oxidase inhibition assay (IC₅₀ protocols aligned with Journal of Medicinal Chemistry 2015, 58, 2397–2407). Where the aldehyde is used in conjunction with difluoromethyl‑substituted anilines, the crude reaction mixture shows a tendency to form an oxazolidine by‑product (up to 15 % LC‑area) when the reaction pH drifts below 4; tight control of acetic acid stoichiometry and stepwise addition of STAB over 30 min is therefore incorporated into the automation script. Pharmaceutical development laboratories operating under this workflow classify the aldehyde as an R&D starting material with a specification derived from ICH Q11 principles—identity by IR (USP <197>), assay ≥ 97.0% by HPLC, and palladium residue ≤ 2 ppm due to the preceding Suzuki coupling step in the aldehyde synthesis. Occupational safety baselines during high‑throughput experimentation reference the ASTM E2672‑22 exposure‑banding framework, with a target airborne concentration of 20 µg m⁻³ for the solid. The terminal output of such scaffold‑hopping programmes is not a commercial product but a collection of 100–500 non‑purine lead candidates; nevertheless, the generated structure‑activity data may later inform an extended‑release formulation candidate that re‑enters a GMP development path.

Cleaning Validation Limits and Cross‑Contamination Risk Assessment for the Thiazole Aldehyde on Multi‑Purpose Manufacturing Lines

When the Febuxostat aldehyde intermediate is handled in a non‑dedicated API facility that also manufactures diuretic or antiplatelet agents, the cleaning validation protocol must establish an acceptable daily exposure (ADE) value for the compound to define maximum allowable carry‑over (MACO) limits on product‑contact surfaces. Based on a repeated‑dose toxicity read‑across from structurally related thiazole‑carboxylate esters and incorporating a composite uncertainty factor of 1000, the ADE for the aldehyde is set at 150 µg day⁻¹; this value is adopted in the site’s health‑based exposure limit (HBEL) monograph per EMA/CHMP/CVMP SWP guidance of June 2018. Using a subsequent product’s minimum daily dose of 5.0 mg and maximum batch size of 80 kg, the MACO is calculated as (150 µg × 80 kg) ÷ (5 mg × 10⁶) = 2.4 g of aldehyde permitted across the entire equipment train. Swab sampling is conducted according to ASTM E3219‑19 on representative surface areas (25 cm²) of the Hastelloy reactor interior, centrifuge bowl, and dryer agitator blades, using Texwipe TX714 swabs pre‑moistened with 0.1 M HCl : methanol 1:1 v/v; recovery studies performed at 0.5–3.0 µg per swab show consistent extraction efficiency of 88–92%, satisfying the acceptance criterion ≥ 70% stipulated in USP <1229.11>. Rinse‑sample analysis relies on LC‑MS/MS in multiple reaction monitoring mode (transition m/z 389.2 → 314.1 for quantification), with a method detection limit of 0.02 ng per injection. During a three‑year review period, the sole cleaning‑validation excursion was recorded when a post‑Febuxostat‑aldehyde batch of a low‑dose corticosteroid exhibited an aldehyde carryover of 4.2 µg per tablet, attributable to insufficient spray‑ball impingement in the 600‑L reactor’s manway region; the corrective action involved modifying the CIP sequence to include an alkaline‑pH 12 sodium hypochlorite‑detergent cycle at 70 °C for 20 min, achieving a 4‑log reduction in aldehyde surface residue to below the revised MACO of 0.6 g. Regulatory submissions for new products introduced onto this equipment line now include an aldehyde‑specific carry‑over risk assessment table cross‑referenced with ICH Q3A(R2) and the European Pharmacopoeia General Chapter 5.20 on metal catalyst residues; although the aldehyde is not metal‑bearing, the chapter’s risk‑management template is adopted for consistency. The terminal product category impacted by this analysis includes all non‑Febuxostat APIs and finished dosage forms produced in the shared facility, ensuring that no batch released to the market exceeds the PDE‑derived limit for the thiazole aldehyde impurity.